Following a request by the company, UCB Pharma, the evaluation has been paused. The committee meeting planned for 19 March 2026 will not go ahead. NICE will continue discussions with the company and will provide an update in Q1 2026 regarding new timelines.
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 363 KB) Published: 14 August 2025